<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0186-4866</journal-id>
<journal-title><![CDATA[Medicina interna de México]]></journal-title>
<abbrev-journal-title><![CDATA[Med. interna Méx.]]></abbrev-journal-title>
<issn>0186-4866</issn>
<publisher>
<publisher-name><![CDATA[Edición y Farmacia S.A. de C.V.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0186-48662019000300370</article-id>
<article-id pub-id-type="doi">10.24245/mim.v35i3.2902</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Diferencias farmacocinéticas entre rifaximina alfa y una rifaximina genérica]]></article-title>
<article-title xml:lang="en"><![CDATA[Pharmacokinetic differences between alpha rifaximin and a generic rifaximin]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Marzoli]]></surname>
<given-names><![CDATA[Gabriela Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Federici]]></surname>
<given-names><![CDATA[Mascia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mascagni]]></surname>
<given-names><![CDATA[Marco]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Maffei]]></surname>
<given-names><![CDATA[Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calanni]]></surname>
<given-names><![CDATA[Fiorella]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Viscomi]]></surname>
<given-names><![CDATA[Giuseppe Claudio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Research Toxicology Centre SpA  ]]></institution>
<addr-line><![CDATA[Roma ]]></addr-line>
<country>Italia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Alfasigma SpA Corporate R&amp;D Department ]]></institution>
<addr-line><![CDATA[Bologna ]]></addr-line>
<country>Italia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>35</volume>
<numero>3</numero>
<fpage>370</fpage>
<lpage>378</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0186-48662019000300370&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0186-48662019000300370&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0186-48662019000300370&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  ANTECEDENTES: Los fármacos que tienen polimorfismo, como la rifaximina, pueden tener diferencias farmacocinéticas según el polimorfo. La rifaximina polimorfa-&#945; (alfa) es un antibiótico no absorbible.  OBJETIVO: Investigar si la farmacocinética de la rifaximina de referencia (&#945;) es distinta de la de una rifaximina genérica en el mercado mexicano.  MATERIAL Y MÉTODO:  Estudio prospectivo experimental del polimorfo con difracción de rayos X, su perfil de solubilidad y la farmacocinética de una dosis única de 100 mg/ kg de cada rifaximina administrada por vía oral en perros Beagle.  RESULTADOS: La rifaximina de referencia fue polimorfo-&#945; (alfa) y la rifaximina genérica resultó polimorfo-&#1082; (kappa). El perfil de solubilidad fue diferente porque el polimorfo-&#1082; fue más soluble que el &#945;. La concentración plasmática máxima (Cmáx), la concentración durante 24 horas (AUC0-t) y la biodisponibilidad relativa fueron 8 a 10 veces mayores con rifaximina genérica (&#1082;) que con la de referencia (&#945;).  CONCLUSIÓN: La rifaximina genérica estudiada tiene farmacocinética distinta del producto de referencia y no puede considerarse del todo un antibiótico no absorbible. Se discuten las posibles implicaciones terapéuticas, especialmente en la seguridad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  BACKGROUND: Drugs with polimorphism, as rifaximin, may have different pharmacokinetic depending on the polymorph. Rifaximin polymorph-&#945; (alfa) is a non-absorbable antibiotic.  OBJECTIVE: To investigate if pharmacokinetic of reference rifaximin (&#945;) is different from a generic rifaximin of the Mexican market.  MATERIAL AND METHOD: A prospective experimental study was done assessing polymorphism with X-ray diffraction, solubility test and pharmacokinetics in Beagle dogs after unique oral dose of 100 mg/kg of each rifaximin.  RESULTS: Reference rifaximin was a polymorph-&#945; (alfa), while generic rifaximin resulted a polymorph-&#1082; (kappa). Solubility profile of both was different, solubility of generic was major than reference rifaximin. Plasma peak concentration (Cmax), area under curve (AUC0-t) and relative bioavailability were 8 to 10 folds higher with generic rifaximin (&#1082;) than reference drug (&#945;).  CONCLUSION: Generic rifaximin has a different pharmacokinetic from the reference rifaximin and the former cannot be considered a non-absorbable antibiotic.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Rifaximina]]></kwd>
<kwd lng="es"><![CDATA[genérica]]></kwd>
<kwd lng="es"><![CDATA[biodisponibilidad]]></kwd>
<kwd lng="en"><![CDATA[Rifaximin]]></kwd>
<kwd lng="en"><![CDATA[Generic]]></kwd>
<kwd lng="en"><![CDATA[Bioavailability]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borka]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Haleblian]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Crystal polymorphism of pharmaceuticals]]></article-title>
<source><![CDATA[Acta Pharm Jugosl]]></source>
<year>1990</year>
<volume>40</volume>
<page-range>71-94</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singhal]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Curatolo]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug polymorphism and dosage form design a practical perspective]]></article-title>
<source><![CDATA[Adv Drug Deliv Rev]]></source>
<year>2004</year>
<volume>56</volume>
<page-range>335-47</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peterson]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Hickey]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Zaworoto]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Almarsson]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expanding the scope of crystal form evaluation in phar- maceutical science]]></article-title>
<source><![CDATA[J Pharm Pharm Sci]]></source>
<year>2006</year>
<volume>9</volume>
<page-range>317-26</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguiar]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Krc]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kinkel]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Samyn]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of polymorphism on the absorption of chloramphenicol palmitate]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>1967</year>
<volume>56</volume>
<page-range>847-53</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pandit]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Gode]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of crystal form on oral absorption of phenylbutazone]]></article-title>
<source><![CDATA[J Int Pharm]]></source>
<year>1984</year>
<volume>21</volume>
<page-range>129-32</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Spanton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Henry]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Quich]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Dziki]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Porter]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ritonavir an extraordinary example of conformational polymorphism]]></article-title>
<source><![CDATA[Pharm Res]]></source>
<year>2001</year>
<volume>18</volume>
<page-range>859-66</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Viscomi]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Campana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Barbanti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Grepioni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Polito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Confortini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Crystal forms of rifaximin and their effect on pharmaceutical properties]]></article-title>
<source><![CDATA[Cryst Eng Comm]]></source>
<year>2008</year>
<volume>10</volume>
<page-range>1074-81</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marzo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ismaili]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomised, crossover study to evaluate the safety and the pharmacokinetic profiles of a single dose (400 mg) of the amorphous rifaximin in comparison with a single dose (400 mg) of Normix(r) (rifaximin-polymorph-a) in healthy volunteers]]></article-title>
<source><![CDATA[Dig Liver Dis]]></source>
<year>2010</year>
<volume>42S</volume>
<page-range>S191-2</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blandizzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Viscomi]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Scarpignato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers]]></article-title>
<source><![CDATA[Drug Res]]></source>
<year>2015</year>
<volume>9</volume>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blandizzi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Viscomi]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Marzo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scarpignato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is generic rifaximin still a poorly absorbed antibiotic A comparison of branded and generic formulations in healthy volunteers]]></article-title>
<source><![CDATA[Pharm Res]]></source>
<year>2014</year>
<volume>85</volume>
<page-range>39-44</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steffen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sack]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Riopel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[ZD]]></given-names>
</name>
<name>
<surname><![CDATA[Stürchler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ericsson]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Therapy of travelers' diarrhea with rifaximin on various continents]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2003</year>
<volume>98</volume>
<page-range>1073-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bourgeois]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ericsson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Steffen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[ZD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea]]></article-title>
<collab>Halpern J et al</collab>
<source><![CDATA[Am J Trop Med Hyg]]></source>
<year>2006</year>
<volume>74</volume>
<page-range>1060-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lembo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chey]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Zakkos]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ringel]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin therapy for pa- tients with irritable bowel syndrome without constipation]]></article-title>
<collab>et al for the TARGET Study Group</collab>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<page-range>22-32</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chong]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lembo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of harm in the pharmacotherapy of irritable bowel syndrome]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2012</year>
<volume>125</volume>
<page-range>381-93</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lembo]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Schoenfeld]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cash]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstock]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of repeat treatment with rifaximin for diarrhea-predominant irritable bowel syndrome (IBS)]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2016</year>
<volume>151</volume>
<page-range>1113-21</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cash]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[SSC]]></given-names>
</name>
<name>
<surname><![CDATA[Weinstock]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Heimanson]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Lembo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life; a secondary analysis of a randomized double-blind, placebocontrolled trial]]></article-title>
<source><![CDATA[Ther Adv Gastroenterol]]></source>
<year>2017</year>
<volume>10</volume>
<page-range>689-99</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Mullen]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Sanyal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Poordad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Neff]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Leevy]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin treatment in hepatic encephalopathy N Engl]]></article-title>
<source><![CDATA[J Med]]></source>
<year>2010</year>
<volume>362</volume>
<page-range>1071-81</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mullen]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Sanyal]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Poordad]]></surname>
<given-names><![CDATA[FE]]></given-names>
</name>
<name>
<surname><![CDATA[Sheikh]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
<name>
<surname><![CDATA[Frederick]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy]]></article-title>
<source><![CDATA[Clin Gastroenterol Hepatol]]></source>
<year>2014</year>
<volume>12</volume>
<page-range>1390-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bajaj]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Barret]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Bortey]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Paterson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Forbes]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prolonged remission from hepatic encephalopathy with rifaximin results of a placebo crossover analysis]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2015</year>
<volume>41</volume>
<page-range>39-45</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Latella]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pimpo]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Sottili]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zippi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Viscido]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chiara- monte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon]]></article-title>
<source><![CDATA[Int J Colorectal Dis]]></source>
<year>2003</year>
<volume>18</volume>
<page-range>55-62</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colecchia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vestito]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pasqui]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzella]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Roda]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Pi- stoia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic uncomplicated colonic diverticular disease]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2007</year>
<volume>13</volume>
<page-range>264-9</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stallinger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eller]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Högenauer]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease]]></article-title>
<source><![CDATA[Wien Klin Wochenschr]]></source>
<year>2014</year>
<volume>126</volume>
<page-range>9-14</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<source><![CDATA[Xifaxan(r) (rifaximin tablets 550 mg. NDA 22-554. Briefing document for Gastrointestinal Drugs Advisory Committee Meeting]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gillum]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Israel]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Polk]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetic drug interactions with antimicrobial agents]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>1993</year>
<volume>25</volume>
<page-range>450-82</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scarpignato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pelosini]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic]]></article-title>
<source><![CDATA[Digestion]]></source>
<year>2006</year>
<volume>73</volume>
<numero>Suppl 1</numero>
<issue>Suppl 1</issue>
<page-range>13-27</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soro]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Pesce]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Raggi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Debbia]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Schito]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentration of rifaximin]]></article-title>
<source><![CDATA[Clin Microbiol Infect]]></source>
<year>1997</year>
<volume>3</volume>
<page-range>147-51</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fietta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cascina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Meloni]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A 10-year survey of Mycobacterium tuberculosis isolates in Pavia and their drug resistance a comparison with other Italian reports]]></article-title>
<source><![CDATA[J Chemother]]></source>
<year>2002</year>
<volume>14</volume>
<page-range>33-40</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novoa-Farías]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Frati-Munari]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Peredo]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Flores-Juárez]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Novoa-García]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Galicia-Tapia]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Susceptibility to rifaximin and other antimicrobial agents of bacteria isolated from acute gastrointestinal infections in Mexico]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>2016</year>
<volume>81</volume>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gatta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Scarpignato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic review with metaanalysis rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2017</year>
<volume>45</volume>
<page-range>604-16</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lees]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Aliabadi]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rational dosing of antimicrobial drugs animal versus humans]]></article-title>
<source><![CDATA[Int J Antimicrob Agents]]></source>
<year>2002</year>
<volume>19</volume>
<page-range>269-84</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parvova]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dauchev]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hristov]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Animal models of human diseases and their significance for clinical studies of new drugs]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2011</year>
<volume>4</volume>
<page-range>19-29</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
